Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OVAFIT-TIL: A Phase Ib Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab in Recurrent Ovarian Cancer

NCT07720180 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT07720180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07720180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OVAFIT-TIL: A Phase Ib Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab in Recurrent Ovarian Cancer
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2032
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer